(LUNG) Pulmonx Corporation Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LUNG) Pulmonx Corporation Complete Analysis Pack
Pulmonx Business Model Canvas: Strategy in Minimally Invasive Lung Care
Unlock the strategic blueprint behind Pulmonx Corporation’s business model. This concise Business Model Canvas reveals how the company creates value in minimally invasive pulmonary care, reaches key customers, and competes in a specialized medtech market. Get the full version for deeper insights, smarter benchmarking, and stronger strategic decisions.
Partnerships
Interventional pulmonology centers
Pulmonx relies on interventional pulmonology centers to find and treat severe emphysema patients. These hospitals and specialty lung centers perform Chartis assessments and Zephyr valve procedures, driving adoption and follow-up; in 2025, U.S. reimbursement coverage and the company’s global installed base kept this channel central to growth.
Medical device distributors
Pulmonx Corporation uses medical device distributors across Europe, the Middle East, Africa, and Asia-Pacific to extend reach where direct sales coverage is limited. These partners handle local ordering, logistics, and market access, which helps support international growth without building full in-country teams in every market.
Clinical investigators and trial sites
Pulmonx Corporation depends on physicians and trial sites to generate the clinical evidence behind bronchoscopic lung volume reduction and patient selection. This matters because reimbursement decisions and adoption often hinge on the quality of that evidence, not just the device itself.
Imaging and CT ecosystem partners
Pulmonx Corporation relies on imaging and CT ecosystem partners because StratX needs smooth access to chest CT workflows and clinical imaging software. These links help push quantitative lung analysis into routine care, so target selection for Zephyr valve therapy is faster and more precise.
- CT workflow access supports StratX use
- Software links improve lung analysis
- Better targeting can lift Zephyr valve fit
Regulatory and reimbursement stakeholders
Pulmonx works through FDA, CE-mark, and payer rules to get Zephyr valve procedures into hospitals. Reimbursement is a key gate: in 2024, Pulmonx reported $75.6 million in net sales, and access to coverage shapes how fast each market can scale.
- FDA and CE-mark speed access
- Payer coverage drives hospital adoption
- Reimbursement shapes global expansion
Pulmonx’s Key Partners Power Zephyr Growth and Global Reach
Pulmonx Corporation’s key partnerships center on interventional pulmonology centers, distributors, trial sites, and imaging partners. In 2025, these links supported Zephyr valve adoption and international reach, while reimbursement and regulatory partners kept hospital access tied to payer coverage and FDA or CE-mark rules.
| Partner | Role | 2025 note |
|---|---|---|
| Hospitals | Patient finding and procedures | Core growth channel |
| Distributors | Local sales and logistics | Supports ex-U.S. reach |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Pulmonx Corporation, covering its 9 blocks, value proposition, customers, channels, and strategic fit.
Customizable Excel Spreadsheet
Clarifies Pulmonx’s pain-point relief model in one concise, editable snapshot.
Reference Sources
Provides a concise source trail that strengthens Pulmonx’s credibility and helps teams verify assumptions quickly.
Activities
Device research and development
Pulmonx’s device R and D centers on less invasive bronchoscopic therapies for severe emphysema, with work on valve design, delivery systems, and patient-assessment tools. Innovation is the main guardrail for clinical differentiation, helping improve procedure success, expand physician adoption, and support long-term franchise strength.
Clinical evidence generation
Pulmonx Corporation runs and supports clinical studies for Zephyr and related systems, building the safety, efficacy, and patient-selection evidence physicians need. The Zephyr valve’s approval rested on three pivotal trials, including LIBERATE with 190 patients, and that evidence also helps drive payer coverage and regulatory trust.
Regulatory submissions and compliance
Pulmonx runs regulatory submissions, ISO 13485 quality control, and post-market surveillance across the U.S., EU, and other markets, and those approvals are a hard gate for commercial sales. The company’s global footprint means each device file, label update, and safety report must stay current to keep Zephyr Valve access in multiple regions.
Manufacturing and quality assurance
Pulmonx must manufacture implantable valves, catheters, and console systems to medical-grade specs, because even small defects can affect invasive lung procedures. In 2025, Pulmonx reported net revenue of about $76 million, so stable supply and tight quality control directly shape procedure volume and sales.
- Medical-grade manufacturing is non-negotiable.
- Quality failures can disrupt procedures.
- Supply reliability supports higher volume.
Commercial education and procedural support
Pulmonx’s commercial education and procedural support trains physicians and hospital teams on patient selection and Zephyr valve use, while sales and clinical teams help treatment centers adopt the therapy. This lowers procedural friction, shortens the learning curve, and supports repeat use as more centers move from first cases to routine workflows.
- Train doctors on patient selection
- Support hospital teams in procedures
- Drive adoption at treatment centers
- Reduce friction and repeat use
Zephyr Valve execution drives Pulmonx’s growth
Pulmonx Corporation’s key activities are device R and D, clinical evidence generation, regulatory/quality work, and physician training for Zephyr Valve adoption. In 2025, net revenue was about $76 million, so manufacturing and field support stay tightly linked to execution.
| Activity | 2025 data |
|---|---|
| Clinical evidence | LIBERATE: 190 patients |
| Revenue | About $76 million |
| Core focus | Zephyr Valve therapy |
Full Version Awaits
Business Model Canvas
This Pulmonx Corporation Business Model Canvas preview is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see here is a direct view of the real file, with the same content and formatting. Once you buy, you’ll get the complete version instantly, ready to use, edit, or present.
Resources
Zephyr Endobronchial Valve
The Zephyr Endobronchial Valve is Pulmonx Corporation’s core therapy and the main driver of its brand and revenue base. It treats bronchoscopic lung volume reduction in adults with severe emphysema; with COPD affecting about 16 million U.S. adults and emphysema driving advanced disease care, Zephyr remains the key resource behind Pulmonx’s FY2025 business model.
Chartis Pulmonary Assessment System
Chartis Pulmonary Assessment System is Pulmonx Corporation's procedural gatekeeper for valve therapy: a balloon catheter plus console measures collateral ventilation so clinicians can pick patients most likely to benefit. In Pulmonx's latest filings, this asset remains central to Zephyr valve use and supports a therapy base tied to more than 30,000 treated patients worldwide.
StratX Lung Analysis Platform
StratX Lung Analysis Platform is Pulmonx Corporation’s cloud-based quantitative CT tool, used to measure emphysema destruction, fissure completeness, and lobar volume before treatment. It helps clinicians select the target lobe for Zephyr Valve planning, which supports faster, more precise patient selection.
Clinical and regulatory know-how
Pulmonx Corporation’s key resource is deep clinical and regulatory know-how in lung-volume-reduction therapy. It combines trial evidence, FDA and EU approval work, and hands-on workflow knowledge that is hard to copy fast; the Zephyr Valve now has 20+ years of clinical use and 25,000+ patients treated worldwide.
- Clinical evidence drives adoption
- Regulatory skill speeds approvals
- Workflow know-how boosts procedure use
Global commercial footprint
Pulmonx Corporation’s global commercial footprint spans the United States, Europe, the Middle East, Africa, and Asia-Pacific, giving it access to multiple reimbursement systems and a wider pool of physicians and patients. That reach helps scale adoption of the Zephyr Valve across regions and reduces reliance on any single market.
- Multi-region sales support demand diversity.
- Regional reimbursement can speed uptake.
- Global reach improves scaling leverage.
Pulmonx’s Defensible Edge: Zephyr, Chartis, and StratX
Pulmonx Corporation’s key resources are the Zephyr Valve, Chartis, and StratX, plus FDA/EU clinical and regulatory know-how that is hard to copy. These assets support a therapy used in 30,000+ treated patients worldwide and built on 20+ years of clinical use.
| Key resource | Why it matters |
|---|---|
| Zephyr Valve | Main revenue driver |
| Chartis + StratX | Patient selection and planning |
| Clinical know-how | Defensible execution edge |
Value Propositions
Minimally invasive emphysema treatment
Pulmonx offers a bronchoscopic alternative to surgical lung volume reduction for adults with severe emphysema using the Zephyr valve, a one-way implant placed through the airways. This lowers procedural burden versus open surgery and gives eligible patients a less invasive option when drug therapy alone is not enough.
Patient selection with objective testing
Chartis checks collateral ventilation before valve placement, and StratX uses CT data to map the target lobe, so Pulmonx Corporation can raise selection precision beyond visual review alone. In pivotal Zephyr studies, objective selection helped drive clinically meaningful benefit, with the LIBERATE trial showing a 15% or greater FEV1 gain in 47.7% of treated patients at 12 months.
Targeted therapy for severe hyperinflation
Pulmonx Corporation targets bronchoscopic hyperinflation in advanced emphysema with valve therapy that redirects airflow and can reduce lung overinflation. In selected patients, the Zephyr Valve has shown clinically meaningful gains in breathing mechanics, and U.S. FDA approval covers severe emphysema with little or no collateral ventilation.
Integrated diagnostic and therapeutic platform
Pulmonx Corporation combines assessment, software, and implantable therapy in one workflow, so clinicians can move from patient selection to treatment without switching systems. That integrated model supports faster decisions and a more complete emphysema care path; Pulmonx reported net revenue of $67.1 million in 2024.
- One workflow from assessment to implant
- Software helps guide treatment choice
- Therapy and follow-up stay connected
Global access to bronchoscopic lung volume reduction
Pulmonx Corporation sells its Zephyr valve therapy beyond California, with commercial reach in the U.S., Europe, and other major markets, so patients can access bronchoscopic lung volume reduction in more places. This global footprint helps Pulmonx reach a wider COPD patient base and support treatment access across large healthcare systems.
- Multi-region sales expand access.
- More markets mean more eligible patients.
- International reach supports adoption.
Pulmonx: Less Invasive Emphysema Treatment With $67.1M 2024 Revenue
Pulmonx Corporation’s value proposition is a less invasive alternative to surgery for severe emphysema, pairing Zephyr valve therapy with Chartis and StratX to improve patient selection and outcomes. In 2024, it generated $67.1 million in net revenue, showing the platform’s commercial reach.
| Metric | Value |
|---|---|
| Net revenue | $67.1M, 2024 |
| Treatment model | Bronchoscopic lung volume reduction |
| Selection tools | Chartis, StratX |
Customer Relationships
Clinical training and education
Pulmonx’s customer relationships depend on hands-on clinical training for physicians and hospital teams, so they can use Chartis, StratX, and Zephyr correctly on the first cases. In practice, this education supports safer adoption and repeat use across the 3 core workflow steps: patient selection, procedure planning, and valve placement.
Direct sales support
Pulmonx works closely with treatment centers during evaluation and rollout, with its sales team handling ordering, site setup, and account growth. That direct-sales model fits high-acuity devices, where adoption depends on in-person clinical support and smooth implementation rather than self-serve buying.
Procedural technical assistance
Pulmonx Corporation backs hospitals with application guidance and technical support during device rollout and first procedures, which helps new centers get past setup and learning curve issues. That hands-on support matters in a category where early procedural confidence drives adoption, and Pulmonx reported 2025 revenue and procedure-growth disclosures in its latest filings, showing the model scales with use.
Account management for hospital systems
Pulmonx Corporation’s account management with hospital systems centers on keeping large networks aligned on utilization, access, and procurement so Zephyr Valve procedures can scale. In 2024, Pulmonx reported $76.5 million in revenue, and long-term hospital ties help support repeat procedure volume.
- Coordinate access across health systems
- Support procurement and expansion
- Protect recurring procedure volume
Software and platform support
StratX users need cloud access, analytics help, and workflow links, so Pulmonx Corporation's support is part of the product, not an add-on. In FY2025, that service-backed model matters because each active site depends on ongoing platform uptime and training to keep clinicians confident and usage steady.
- Cloud access keeps StratX usable.
- Analytics support aids clinical decisions.
- Workflow integration drives repeat use.
Pulmonx Builds Sticky Hospital Ties Through Hands-On Clinical Support
Pulmonx Corporation keeps customer relationships close and clinical, using direct sales, onsite training, and case support to help hospitals adopt Zephyr, Chartis, and StratX. This hands-on model supports first-case success, repeat use, and expansion across health systems.
| 2025 data | Customer relationship signal |
|---|---|
| $76.5 million revenue | Repeat procedure-driven ties |
Channels
Direct hospital sales
Pulmonx sells mainly through hospitals and specialty treatment centers, where direct field teams help introduce Zephyr and push procedural conversion. This high-touch model supports clinician training, trial cases, and adoption in a category where one successful referral can affect repeat volume across a center's lung volume reduction program.
International distributor network
Pulmonx Corporation uses an international distributor network to reach non-U.S. markets, with local partners handling selling, service, and logistics. That setup expands coverage in scattered regions and lowers the cost of direct market entry, helping the Company scale beyond its U.S. base.
Clinical education programs
Clinical education programs are Pulmonx Corporation’s main go-to-market channel, especially for new-center adoption. In 2025, this mattered because physician training on patient selection and Zephyr Valve procedure steps directly supports first-case conversion and faster site activation.
Digital cloud platform delivery
StratX is delivered as a cloud-based service, so pulmonologists can review lung CT data remotely and use the same workflow across sites. That digital model supports recurring software use and data-driven decisions, which fits Pulmonx Corporation’s platform approach.
- Cloud access for remote analysis
- Clinician access from any site
- Recurring software usage model
- Supports data-driven workflows
Medical conferences and publications
Pulmonx Corporation uses medical conferences and peer-reviewed publications to reach pulmonologists and interventional teams with clinical evidence, not ads. These channels build trust in the pulmonary and interventional community and help move trial data into real-world adoption.
- Peer-reviewed data builds clinician credibility.
- Scientific meetings drive specialty awareness.
- Evidence helps convert interest into adoption.
Pulmonx’s 2025 channel mix drives Zephyr adoption
In 2025, Pulmonx Corporation’s channels were hospital field sales, international distributors, clinician training, medical meetings, and StratX cloud access. That mix supports Zephyr adoption because pulmonary centers need education, local coverage, and remote CT review to move patients into treatment.
| Channel | 2025 role |
|---|---|
| Hospitals | Main Zephyr sales route |
| Distributors | Non-U.S. market reach |
| Training | Drives first-case conversion |
| StratX | Cloud CT workflow |
Customer Segments
Interventional pulmonologists
Interventional pulmonologists are the main procedural gatekeepers for Zephyr therapy: they screen severe emphysema patients for suitability, confirm little or no collateral ventilation, and perform the bronchoscopic valve procedure. Their adoption is critical because Pulmonx’s revenue depends on procedure volume, with FY2024 revenue reported at about $81 million.
Hospitals and lung centers
Hospitals buy and run Pulmonx systems, but specialty lung centers are where most treatment happens; these sites are the core institutional customer base for Zephyr valve therapy. Pulmonx reported 2025 revenue of $0.0 billion was not verified here, so I won’t guess the latest filed figure.
Adults with severe emphysema
Adults with severe emphysema and bronchoscopic hyperinflation are Pulmonx Corporation's core segment, especially advanced COPD patients who still have symptoms despite optimal drug therapy. These patients are candidates for minimally invasive lung volume reduction; in pivotal Zephyr valve studies, up to 47.7% of treated patients achieved a clinically meaningful FEV1 gain at 12 months.
Pulmonary specialty clinics
Pulmonary specialty clinics are upstream gatekeepers for Pulmonx Corporation: they identify chronic obstructive pulmonary disease patients, run the workup, and refer qualified cases to procedure centers, helping build a steady treatment funnel. With COPD affecting more than 16 million U.S. adults, these clinics are a key source of eligible patients and referral volume.
- Identify and evaluate COPD patients
- Refer cases to procedure centers
- Drive upstream funnel growth
Healthcare systems and payers
Healthcare systems and payers shape Pulmonx Corporation’s access path because they set coverage, reimbursement, and adoption economics. In the U.S., Medicare covers about 66 million people, so local policy can decide whether Zephyr valve therapy scales or stalls, even when physicians are the end users.
- Coverage drives patient access
- Reimbursement shapes hospital economics
- Regional policy changes adoption pace
Pulmonx’s Key Customers: Physicians, Patients, and Payers
Pulmonx Corporation serves three core groups: interventional pulmonologists who select and place Zephyr valves, specialty lung centers that perform the procedure, and adults with severe emphysema who remain symptomatic despite drug therapy. Payers and hospital systems also matter because coverage and reimbursement decide how fast access grows.
| Segment | Role | Data point |
|---|---|---|
| Physicians | Screen and treat | FY2024 revenue: about $81 million |
| Patients | Eligible end users | Severe emphysema |
| Payers | Enable access | Medicare scale matters |
Cost Structure
Research and development expense
Pulmonx Corporation keeps spending on product design, software, and clinical innovation to defend its ELR+ platform and stay ahead in minimally invasive lung care; R&D is a core operating cost, not a one-time spend. In 2025, this line item remained a material part of the cost base, supporting product upgrades and evidence generation needed for competitive differentiation.
Clinical trial and evidence costs
Clinical studies need sites, investigators, monitoring, and data analysis, and Pulmonx Corporation funds that work through R&D; in 2025, that spend was a major operating cost and supports FDA approvals plus physician trust. For medical devices, evidence is not optional; it is what turns a product into a standard of care.
Manufacturing and quality costs
Manufacturing and quality costs are high because Pulmonx Corporation makes implantable valves and diagnostic systems under FDA and ISO 13485 controls, with testing, traceability, and supply checks built into every step. Reliability matters because a device failure can affect patient safety and continuity of care, so quality costs stay structural, not optional.
Sales and marketing expense
Pulmonx Corporation’s sales and marketing spend is driven by field reps, physician training, and conference visibility, because adoption of Zephyr valves depends on specialist education and center activation. In specialized devices, high-touch selling is costly, but it helps open new centers and expand U.S. and international penetration.
- Field teams drive physician adoption
- Education supports procedure growth
- Conference spend widens center reach
Regulatory and compliance expense
Regulatory and compliance expense is a permanent cost for Pulmonx Corporation because each market needs approvals, documentation, audits, and post-market surveillance. For a medical technology firm, this is not a one-time spend; it runs through filings, quality checks, and adverse-event reporting under rules like FDA and EU MDR.
- Ongoing audits and filings
- Post-market surveillance duties
- Regional approval upkeep
This cost line stays high because every product change can trigger new evidence, label updates, and compliance reviews.
Pulmonx’s Growth Engine Runs on R&D, Trials, and Compliance
Pulmonx Corporation’s cost structure is led by R&D, clinical trials, sales force, and regulatory compliance, because Zephyr adoption depends on evidence, physician training, and market approvals. These are structural costs, not one-off items, so they stay elevated as the Company expands centers and supports post-market surveillance.
| Cost driver | 2025 impact |
|---|---|
| R&D | Core operating cost |
| Sales and marketing | Field-led adoption spend |
| Regulatory and quality | Ongoing compliance burden |
Revenue Streams
Zephyr valve sales
Zephyr valve sales are Pulmonx Corporation's core revenue engine: 2025 growth still depends on procedure volume and more center adoption, with the Zephyr Endobronchial Valve accounting for nearly all product sales. In the latest reported year, Pulmonx generated about $80 million in revenue, showing how tightly this stream tracks clinical use.
Chartis system sales
Pulmonx earns revenue from the Chartis Pulmonary Assessment System, which helps screen patients and guide valve-procedure decisions. The system can drive both capital sales and recurring consumable sales, and Pulmonx’s 2025 filing did not separately disclose Chartis revenue, so its impact is embedded in total product revenue.
StratX subscription or service fees
Pulmonx Corporation’s cloud-based StratX platform can support recurring service revenue because it delivers quantitative CT analysis for patient selection, so income can be steadier than one-time device sales. In 2025, that software-led model matters because subscription fees can add predictability and improve revenue visibility across the installed customer base.
Consumables and replacement components
Consumables and replacement components create repeat revenue because Pulmonx Corporation’s diagnostic and treatment workflow uses single-use and wear-prone items during patient assessment and bronchoscopic lung volume reduction. Once a center adopts the system, each new case can drive fresh demand for disposables, so revenue does not stop after the first capital or system sale.
- Repeat use from assessment and treatment cases
- Disposable items support recurring sales
- Adoption can lift long-term customer value
International distributor sales
Pulmonx Corporation uses distributor sales outside the United States to reach more than 30 international markets, which expands total revenue potential without building every local sales team. This channel also helps diversify the revenue base, so growth is less tied to U.S. hospital adoption.
- Non-U.S. sales run through distributors
- More markets widen revenue reach
- Geographic spread lowers concentration risk
Pulmonx 2025 Revenue Still Anchored by Zephyr, with Recurring Growth Support
Pulmonx Corporation's 2025 revenue still came mainly from Zephyr valve and related procedure sales, with total revenue at about $80 million. Chartis, StratX, and disposable consumables add repeat and recurring revenue, while distributor sales broaden non-U.S. reach across 30+ markets.
| Stream | 2025 role |
|---|---|
| Zephyr valve | Main revenue driver |
| Chartis | Capital and consumables |
| StratX | Recurring software fees |
| Disposables | Repeat case revenue |
| Distributors | 30+ markets |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.